COVID19AM: Development and Phase II clinical trial to demonstrate the efficacy of the neutralising antibody COR-101 for the treatment of hospitalised patients with moderate to severe COVID-19 disease (CORAMAR)
- Funded by Federal Ministry of Research, Technology and Space (BMFTR)
- Total publications:0 publications
Grant number: 16LW0107
Grant search
Key facts
Disease
COVID-19Start & end year
20222022Known Financial Commitments (USD)
$6,339,200.51Funder
Federal Ministry of Research, Technology and Space (BMFTR)Research Location
GermanyLead Research Institution
CORAT Therapeutics GmbHResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Clinical trials for disease managementSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Clinical Trial, Phase IIBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified